SANGAMO THERAPEUTICS INC (SGMO) Stock News
NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD
SGMO Latest News, Press Relases and Analysis
Tuesday's pre-market session: top gainers and losers
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -27.27% and 29.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ARMP
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 312.68% and 215.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: NVAX
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: RGNX
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: QGEN
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption
On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.
